Compare JD.Com Inc (JD) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JD.Com Inc vs GeneDx Holdings Corp — how do they compare? JD.Com Inc trades at $27.1 (market cap $36.62B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: JD.Com Inc is far larger — about 18.1× GeneDx Holdings Corp's market cap, and JD.Com Inc pays a 3.72% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold JD.Com Inc for 85 Days and GeneDx Holdings Corp for 19 Days on average.
| JD | WGS | |
|---|---|---|
Market Cap | $36.62B | $2.02B |
Volume | 6,571,477 | 734,640 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.53 | $167.51 |
52-Week Low | $25.19 | $34.51 |
Typical Hold Time | 85 Days | 19 Days |
Enterprise Value | $19.26B | $2.05B |
Dividend Yield | 3.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JD.com (JD) trades at $27.09, up 0.22% on the day, with a bullish technical signal despite mixed moving averages. The stock is deeply undervalued with a P/E of 17.9 and P/S of 0.2, supported by strong cash flow and a robust balance sheet with $234 billion in cash. Recent Q2 2026 earnings beat expectations with EPS of $0.93, and the company is progressing on its $2.5 billion acquisition of Ceconomy, pending EU approval (Reuters, 2026-10-02).
The outlook is positive with a consensus price target of $35.86, implying 32% upside, and 70% of analysts rate it a Buy. Risks include revenue declines, regulatory scrutiny from China and the EU, and competitive pressures. The stock's discount to intrinsic value and strong liquidity position offer a compelling opportunity for long-term investors despite near-term headwinds.
GeneDx (WGS) trades at $68.09, down 0.64% today, with a bearish technical signal despite bullish oscillators showing oversold conditions. The company reported mixed Q2 2026 results with revenue beating expectations but negative profitability metrics, including a -23.4% net income margin. Recent news highlights product launches and industry recognition, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth opportunity in genomic testing with strong analyst support, but faces significant execution risks from persistent losses and high valuation multiples. Key catalysts include continued revenue growth and path to profitability, while risks include competitive pressures and cash flow challenges from negative operating cash flow in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About JD.Com Inc
JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
